Paper7828295
Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group.
Crozier I and 9 others. Circulation, 1995. Cited by 247 papers, by iCite.
Cite this record
ConductScience Library. Losartan in heart failure. Hemodynamic effects and tolerability. Losartan Hemodynamic Study Group. Papers, record 7828295. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7828295
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Angiotensin II | Major topic |
| Angiotensin Receptor Antagonists | Major topic |
| Biphenyl Compounds | Major topic |
| Heart Failure | Major topic |
| Hemodynamics | Major topic |
| Imidazoles | Major topic |
| Tetrazoles | Major topic |
| Aged | |
| Double-Blind Method | |
| Female | |
| Humans | |
| Losartan | |
| Male | |
| Middle Aged | |
| Norepinephrine | |
| Renin |
Source PubMed
Cited by41
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 247 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 39562706 | Angiotensin-II drives changes in microglia-vascular interactions in rats with heart failure. | Commun Biol | 2024 | https://conductscience.org/library/papers/39562706 | PubMed |
| 39554401 | Exploring Hypertension: The Role of AT1 Receptors, Sartans, and Lipid Bilayers. | ACS Omega | 2024 | https://conductscience.org/library/papers/39554401 | PubMed |
| 37035922 | Angiotensin II-Mediated Neuroinflammation in the Hippocampus Contributes to Neuronal Deficits and Cognitive Impairment in Heart Failure Rats. | Hypertension | 2023 | https://conductscience.org/library/papers/37035922 | PubMed |
| 36918917 | Arterial stiffness and its associations with left ventricular diastolic function according to heart failure types. | Clin Hypertens | 2023 | https://conductscience.org/library/papers/36918917 | PubMed |
| 31474857 | Testing the Translational Power of the Zebrafish: An Interspecies Analysis of Responses to Cardiovascular Drugs. | Front Pharmacol | 2019 | https://conductscience.org/library/papers/31474857 | PubMed |
| 31433752 | Angiotensin Type 1 Receptor Blockers in Heart Failure. | Curr Drug Targets | 2020 | https://conductscience.org/library/papers/31433752 | PubMed |
| 27867524 | Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/AHA guidelines. | ESC Heart Fail | 2016 | https://conductscience.org/library/papers/27867524 | PubMed |
| 25852239 | Under-Utilization of Implantable Cardioverter Defibrillators in Patients with Heart Failure - The Current State of Sudden Cardiac Death Prophylaxis. | Indian Pacing Electrophysiol J | 2015 | https://conductscience.org/library/papers/25852239 | PubMed |
| 22513909 | Angiotensin receptor blockers for heart failure. | Cochrane Database Syst Rev | 2012 | https://conductscience.org/library/papers/22513909 | PubMed |
| 20697885 | Losartan reduces mortality in a genetic model of heart failure. | Naunyn Schmiedebergs Arch Pharmacol | 2010 | https://conductscience.org/library/papers/20697885 | PubMed |
| 16933064 | Future pharmacologic agents for treatment of heart failure in children. | Pediatr Cardiol | 2006 | https://conductscience.org/library/papers/16933064 | PubMed |
| 16060962 | Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. | Respir Res | 2005 | https://conductscience.org/library/papers/16060962 | PubMed |
| 15188948 | Beneficial effect of candesartan treatment on cardiac autonomic nervous activity in patients with chronic heart failure: simultaneous recording of ambulatory electrocardiogram and posture. | Clin Cardiol | 2004 | https://conductscience.org/library/papers/15188948 | PubMed |
| 12673184 | Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders. | J Nucl Cardiol | 2003 | https://conductscience.org/library/papers/12673184 | PubMed |
| 12671327 | Drugs that interrupt the renin-angiotensin system should be among the preferred initial drugs to treat hypertension. | J Clin Hypertens (Greenwich) | 2003 | https://conductscience.org/library/papers/12671327 | PubMed |
| 12093312 | Angiotensin II receptor antagonists in chronic heart failure: where do they fit? | Drugs | 2002 | https://conductscience.org/library/papers/12093312 | PubMed |
| 11888333 | Population pharmacokinetic-pharmacodynamic modelling of angiotensin receptor blockade in healthy volunteers. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/11888333 | PubMed |
| 11817974 | Treatment of heart failure in patients with diabetes mellitus. | Drugs | 2002 | https://conductscience.org/library/papers/11817974 | PubMed |
| 11714415 | Angiotensin receptor blockers in heart failure after the ELITE II trial. | Curr Control Trials Cardiovasc Med | 2000 | https://conductscience.org/library/papers/11714415 | PubMed |
| 11696265 | Dilated Cardiomyopathy. | Curr Treat Options Cardiovasc Med | 2001 | https://conductscience.org/library/papers/11696265 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7828295
GET https://conductscience.org/api/papers/v1/7828295/cited_by?page=2